Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Provention Bio management to meet virtually with JMP Securities » 04:55
10/04/22
10/04
04:55
10/04/22
04:55
PRVB

Provention Bio

$4.53 /

+0.04 (+0.89%)

Virtual Meeting to be…

Virtual Meeting to be held on October 4 hosted by JMP Securities.

ShowHide Related Items >><<
PRVB Provention Bio
$4.53 /

+0.04 (+0.89%)

PRVB Provention Bio
$4.53 /

+0.04 (+0.89%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.53 /

+0.04 (+0.89%)

Friday
Conference/Events
Cantor biotech/biopharma analyst to hold analyst/industry conference call » 10:45
09/30/22
09/30
10:45
09/30/22
10:45
NVO

Novo Nordisk

$100.26 /

-0.2 (-0.20%)

, LLY

Eli Lilly

$324.59 /

-5.87 (-1.78%)

, PRVB

Provention Bio

$4.54 /

+0.135 (+3.06%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.54 /

+0.135 (+3.06%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

09/30/22 Argus
Eli Lilly price target raised to $360 from $315 at Argus
09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
PRVB Provention Bio
$4.54 /

+0.135 (+3.06%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.54 /

+0.135 (+3.06%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

Conference/Events
Cantor biotech/biopharma analysts to hold analyst/industry conference call » 10:45
09/30/22
09/30
10:45
09/30/22
10:45
NVO

Novo Nordisk

$100.26 /

-0.2 (-0.20%)

, LLY

Eli Lilly

$324.59 /

-5.87 (-1.78%)

, PRVB

Provention Bio

$4.54 /

+0.135 (+3.06%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.54 /

+0.135 (+3.06%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

09/30/22 Argus
Eli Lilly price target raised to $360 from $315 at Argus
09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
PRVB Provention Bio
$4.54 /

+0.135 (+3.06%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.54 /

+0.135 (+3.06%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

NVO Novo Nordisk
$100.26 /

-0.2 (-0.20%)

LLY Eli Lilly
$324.59 /

-5.87 (-1.78%)

Conference/Events
Cantor Fitzgerald biotech/pharma analysts hold analyst/industry conference call » 10:25
09/30/22
09/30
10:25
09/30/22
10:25
NVO

Novo Nordisk

$100.23 /

-0.23 (-0.23%)

, LLY

Eli Lilly

$323.83 /

-6.63 (-2.01%)

, PRVB

Provention Bio

$4.52 /

+0.115 (+2.61%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.52 /

+0.115 (+2.61%)

NVO Novo Nordisk
$100.23 /

-0.23 (-0.23%)

LLY Eli Lilly
$323.83 /

-6.63 (-2.01%)

NVO Novo Nordisk
$100.23 /

-0.23 (-0.23%)

09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
LLY Eli Lilly
$323.83 /

-6.63 (-2.01%)

09/30/22 Argus
Eli Lilly price target raised to $360 from $315 at Argus
09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
PRVB Provention Bio
$4.52 /

+0.115 (+2.61%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.52 /

+0.115 (+2.61%)

NVO Novo Nordisk
$100.23 /

-0.23 (-0.23%)

LLY Eli Lilly
$323.83 /

-6.63 (-2.01%)

NVO Novo Nordisk
$100.23 /

-0.23 (-0.23%)

LLY Eli Lilly
$323.83 /

-6.63 (-2.01%)

NVO Novo Nordisk
$100.23 /

-0.23 (-0.23%)

LLY Eli Lilly
$323.83 /

-6.63 (-2.01%)

NVO Novo Nordisk
$100.23 /

-0.23 (-0.23%)

LLY Eli Lilly
$323.83 /

-6.63 (-2.01%)

Conference/Events
Cantor biotech/biopharma analysts to hold analyst/industry conference call » 04:55
09/30/22
09/30
04:55
09/30/22
04:55
NVO

Novo Nordisk

$100.46 /

+1.1 (+1.11%)

, LLY

Eli Lilly

$330.02 /

-4.06 (-1.22%)

, PRVB

Provention Bio

$4.42 /

-0.22 (-4.74%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

Conference/Events
Cantor biotech/biopharma analyst to hold analyst/industry conference call » 04:55
09/30/22
09/30
04:55
09/30/22
04:55
NVO

Novo Nordisk

$100.46 /

+1.1 (+1.11%)

, LLY

Eli Lilly

$330.02 /

-4.06 (-1.22%)

, PRVB

Provention Bio

$4.42 /

-0.22 (-4.74%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

Conference/Events
Cantor Fitzgerald biotech/pharma analysts hold analyst/industry conference call » 04:55
09/30/22
09/30
04:55
09/30/22
04:55
NVO

Novo Nordisk

$100.46 /

+1.1 (+1.11%)

, LLY

Eli Lilly

$330.02 /

-4.06 (-1.22%)

, PRVB

Provention Bio

$4.42 /

-0.22 (-4.74%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.42 /

-0.22 (-4.74%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

NVO Novo Nordisk
$100.46 /

+1.1 (+1.11%)

LLY Eli Lilly
$330.02 /

-4.06 (-1.22%)

Over a week ago
Conference/Events
Provention Bio management to meet virtually with Oppenheimer » 04:55
09/28/22
09/28
04:55
09/28/22
04:55
PRVB

Provention Bio

$4.34 /

+0.225 (+5.47%)

Virtual Meetings to be…

Virtual Meetings to be held on September 27-28 hosted by Oppenheimer.

ShowHide Related Items >><<
PRVB Provention Bio
$4.34 /

+0.225 (+5.47%)

PRVB Provention Bio
$4.34 /

+0.225 (+5.47%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.34 /

+0.225 (+5.47%)

Conference/Events
Provention Bio management to meet virtually with JMP Securities » 13:37
09/27/22
09/27
13:37
09/27/22
13:37
PRVB

Provention Bio

$4.31 /

+0.2 (+4.87%)

Virtual Meeting to be…

Virtual Meeting to be held on October 4 hosted by JMP Securities.

ShowHide Related Items >><<
PRVB Provention Bio
$4.31 /

+0.2 (+4.87%)

PRVB Provention Bio
$4.31 /

+0.2 (+4.87%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.31 /

+0.2 (+4.87%)

Conference/Events
Cantor biotech/biopharma analyst to hold analyst/industry conference call » 12:39
09/27/22
09/27
12:39
09/27/22
12:39
NVO

Novo Nordisk

$95.29 /

+0.02 (+0.02%)

, LLY

Eli Lilly

$309.41 /

+1.16 (+0.38%)

, PRVB

Provention Bio

$4.28 /

+0.17 (+4.14%)

Biopharma and Biotech…

Biopharma and Biotech Analysts Chen & Kim and Biotech Analyst Agrawal, along with Dr. Modarressi, Cardiometabolic Expert, discuss sizing the obesity opportunity and recent developments in diabetes on an Analyst/Industry conference call to be held on September 30 at 11 am. Webcast Link

ShowHide Related Items >><<
PRVB Provention Bio
$4.28 /

+0.17 (+4.14%)

NVO Novo Nordisk
$95.29 /

+0.02 (+0.02%)

LLY Eli Lilly
$309.41 /

+1.16 (+0.38%)

NVO Novo Nordisk
$95.29 /

+0.02 (+0.02%)

09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
09/02/22 H.C. Wainwright
Forma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
09/01/22 Oppenheimer
Forma Therapeutics downgraded to Perform from Outperform at Oppenheimer
08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
LLY Eli Lilly
$309.41 /

+1.16 (+0.38%)

09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/06/22 Morgan Stanley
Biogen named a 'Catalyst Driven Idea' at Morgan Stanley
PRVB Provention Bio
$4.28 /

+0.17 (+4.14%)

09/20/22 Jefferies
Provention Bio initiated with a Buy at Jefferies
08/04/22 Chardan
Provention Bio price target lowered to $21 from $22.50 at Chardan
07/11/22 H.C. Wainwright
Provention Bio price target lowered to $18 from $25 at H.C. Wainwright
07/01/22 Cantor Fitzgerald
Cantor reiterates Overweight rating on Provention Bio after PDUFA extension
PRVB Provention Bio
$4.28 /

+0.17 (+4.14%)

NVO Novo Nordisk
$95.29 /

+0.02 (+0.02%)

LLY Eli Lilly
$309.41 /

+1.16 (+0.38%)

NVO Novo Nordisk
$95.29 /

+0.02 (+0.02%)

LLY Eli Lilly
$309.41 /

+1.16 (+0.38%)

NVO Novo Nordisk
$95.29 /

+0.02 (+0.02%)

LLY Eli Lilly
$309.41 /

+1.16 (+0.38%)

NVO Novo Nordisk
$95.29 /

+0.02 (+0.02%)

LLY Eli Lilly
$309.41 /

+1.16 (+0.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.